Featured Sponsor Video

CALQUENCE® (acalabrutinib) Long-Term Data – Dr Brem, MD

Please see Full Prescribing information: https://qr.short.az/CalquenceUSPI

This video is intended for US healthcare professionals only.

This video is sponsored by AstraZeneca.

Elizabeth Brem, MD, discusses CALQUENCE efficacy and safety results in chronic lymphocytic leukemia (CLL) patients, including long-term follow-up data and her personal experience treating patients with CLL. Topics include the overview and results of ELEVATE-TN, ASCEND and ELEVATE-RR phase 3 trials.

Select Safety Information

Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) are diarrhea, upper respiratory tract infection, headache, musculoskeletal pain, lower respiratory tract infection, and fatigue. The most common Grade 3 or 4 laboratory abnormalities (≥10%) are absolute neutrophil count decreased, absolute lymphocyte count decreased, platelets decreased, and hemoglobin decreased.

Indication and Usage
CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

CALQUENCE® (acalabrutinib) Safety Data – Dr Levy, MD

Please see Full Prescribing Information: https://qr.short.az/CalquenceUSPI

This video is intended for US healthcare professionals only.

This video is sponsored by AstraZeneca.

Yair Levy, MD emphasizes the importance of cardiovascular risks in chronic lymphocytic leukemia (CLL) patients and discusses CALQUENCE safety profile, including select cardiovascular safety data. Topics include the overview and results of ELEVATE-TN, ASCEND and ELEVATE-RR phase 3 trials, including select cardiovascular safety data and discontinuation rates.

Select Safety Information

Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, cardiac arrhythmias, and hepatotoxicity, including drug-induced liver injury. The most common adverse reactions (≥30%) are diarrhea, upper respiratory tract infection, headache, musculoskeletal pain, lower respiratory tract infection, and fatigue. The most common Grade 3 or 4 laboratory abnormalities (≥10%) are absolute neutrophil count decreased, absolute lymphocyte count decreased, platelets decreased, and hemoglobin decreased.

Indication and Usage
CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

CALQUENCE is a registered trademark of the AstraZeneca group of companies. ©2025 AstraZeneca. All rights reserved. US-99204 Last Updated 4/25